Analysis Research

 
Stock Quotes for Analysis Research top ^
  • Industry: Software - Application
  • Sector: Technology
  • Stock Type: Classic Growth
Sign-up for iaic investment picks
  • Industry: Software - Application
  • Sector: Technology
  • Stock Style: Large Core
  • Stock Type: Slow Growth
Sign-up for iaic investment picks

 
Fund Quotes for Analysis Research top ^
  • Category: Nontraditional Bond
  • Morningstar Rating: 2 Stars
Sign-up for flsmx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsfx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsix investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 3 Stars
Sign-up for flsrx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 1 Stars
Sign-up for flslx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 2 Stars
Sign-up for flslx investment picks
  • Category: Nontraditional Bond
  • Morningstar Rating: 2 Stars
Sign-up for FLSLX investment picks

 
News Articles for Analysis Research top ^
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (A pixaban after the initial M anagement of P u L monary embol I sm and deep vein thrombosis with F irst-line therap Y - EXT ended Treatment). The analysis evaluated clinical and demographic predictors of all-cause hospitalization in patients with VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Results from this analysis demonstrated that during the 12-month extended treatment of VTE, Eliquis significantly reduced the risk of hospitalization versus placebo.
Sign-up for Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE) investment picks
LA JOLLA, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX) , a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced results from a pre-specified interim subgroup analysis of the ongoing open-label ARC-HD Switch study in which the clinical experience of switching subjects' treatment from tetrabenazine to SD-809 was evaluated.
Sign-up for Auspex Pharmaceuticals Announces Data From Interim Analysis of ARC-HD Switch Trial Demonstrating Clinical Activity of SD-809 investment picks
2014/9/4
The retirement plan landscape is stabilizing as fewer U.S. companies last year moved from defined benefit (DB) plans to offering only a defined contribution (DC) plan to new salaried employees than in any other year over the past decade, according to a new analysis by global professional services company Towers Watson (NYSE, NASDAQ: TW). The analysis also found that a few industry sectors — insurance and utilities — are bucking the trend from DB to DC plans.
Sign-up for Retirement Plan Landscape Stabilizing as Fewer Fortune 500 Companies Shifting Defined Benefit Plans to 401(k)s, Towers Watson Analysis Finds investment picks
2014/8/13
Phase III Trial Is Alive And Well; "Hint Of Failure" A Complete Fabrication; No Interim Analysis of Efficacy Done; 55 Patients' Positive Data Independently Collected.
Sign-up for NW BIO CORRECTS ONGOING FALSE CLAIMS BY FEUERSTEIN ABOUT PHASE III TRIAL OF DCVAX®-L, AND INTERIM ANALYSIS investment picks
Last Patient Completes 18-Month Primary Treatment Period - Top-Line Data on Track to Report in 3Q14 96% of Patients with Amenable Mutations Elected to Continue in 12-Month Treatment Extension Statistical Analysis Plan Finalized CRANBURY, N.J., June 30, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) , a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today provided updates and detailed the statistical analysis plan for its second Phase 3 study ( Study 012 ) of the oral small molecule pharmacological chaperone migalastat HCl ("migalastat") monotherapy for Fabry patients with amenable mutations.
Sign-up for Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012 investment picks
IRVINE, Calif., July 31, 2014 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) , a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that its SNP-based chromosomal microarray analysis (CMA) test for miscarriage analysis, the CombiSNP™ Array for Pregnancy Loss , or products of conception, has received conditional approval from the New York Department of Health (NYDOH). This approval is for testing on fresh and formalin fixed paraffin embedded (FFPE) patient samples.
Sign-up for CombiMatrix's SNP-Based Miscarriage Analysis Test Granted Conditional Approval From New York State Department of Health investment picks
Analgesia in a subset of patients (50%), suggests therapeutic potential for Dex-IN in Post Op Day 1 MALVERN, Pa., Sept.
Sign-up for Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN investment picks
HILLSBORO, Ore., July 30, 2014 (GLOBE NEWSWIRE) -- FEI (Nasdaq:FEIC) today announced two new products that speed up the imaging and analysis time for metals researchers and industrial failure analysis labs.
Sign-up for FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research investment picks
--More than $986 billion in risk is concentrated within 15 major metro areas--
Sign-up for 2014 CoreLogic Storm Surge Analysis Identifies More Than 6.5 Million US Homes with Total Reconstruction Value of Nearly $1.5 Trillion at Risk of Hurricane Storm Surge Damage investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Analysis Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Amtrust Financial Services  |  Next: Analysis Shows